Category: 3. Business

  • Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA USA – English USA – English

    STOCKHOLM, Jan. 26, 2026 /PRNewswire/ — BioArctic AB’s (publ) (STO: BIOA B) partner Eisai announced today that the supplemental Biologics License Application (sBLA) for Leqembi Iqlik subcutaneous autoinjector (SC-AI) as a weekly starting dose has been granted Priority Review by the U.S. Food and Drug Administration (FDA). Leqembi is indicated for the treatment of Alzheimer’s disease in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early Alzheimer’s disease). A Prescription Drug User Fee Act (PDUFA) action date is set for May 24, 2026. If approved, Leqembi Iqlik would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease.

    Should the FDA approve the Leqembi Iqlik 500 mg subcutaneous (SC) dosing regimen (two 250 mg injections), the autoinjector could be used to administer a once-weekly starting dose, as an alternative to the current bi-weekly intravenous (IV) dosing. This would enable patients and care partners to choose SC administration at home for both treatment initiation and the currently approved maintenance therapy (360 mg), offering the option of SC or IV administration throughout the entire treatment journey. The injection time for each Leqembi Iqlik autoinjector takes approximately 15 seconds per each 250 mg injection. The SC formulation also has the potential to reduce healthcare resources associated with IV dosing, such as infusion preparation and nurse monitoring, while streamlining the overall Alzheimer’s disease treatment pathway.

    The sBLA is supported by data evaluating SC administration of lecanemab across a range of doses and as part of sub-studies within the Phase 3 Clarity Alzheimer’s disease open-label extension (OLE) following the 18-month core study in individuals with early Alzheimer’s disease. Data show that once-weekly administration of the 500 mg of SC-AI achieved equivalent exposure to once every two weeks IV administration and similar clinical and biomarker benefits. SC administration demonstrated a safety profile similar to IV administration, with less than 2% incidence of systemic injection or infusion-related reactions.

    Alzheimer’s disease is a progressive, relentless disease, with amyloid beta (Aβ) and tau as hallmarks, that is caused by a continuous underlying neurotoxic process driven by protofibrils* (PF) that begins before amyloid plaque removal and continues afterward[1],[2],[3]. Only Leqembi fights Alzheimer’s disease in two ways – targeting both PF and amyloid plaque, which can impact tau downstream.

    Please see full Prescribing Information for Leqembi in the US, including Boxed WARNING.

    This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on January 26, 2026, at 00:30 CET.

    For further information, please contact: 
    Oskar Bosson, VP Communications and Investor Relations
    E-mail: [email protected]
    Telephone: +46 704 107 180

    Jenny Ljunggren, External Communications and Investor Relations Manager
    E-mail: [email protected]
    Telephone: +46 76 013 86 08

    About lecanemab (Leqembi®)
    Lecanemab is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).

    Lecanemab is approved in 53 countries and is under regulatory review in 7 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks is approved in the United Kingdom, China, the U.S. and other countries, and applications have been filed in 4 countries and regions. In the U.S., Leqembi Iqlik™ is approved for subcutaneous dosing with an autoinjector for maintenance treatment of early Alzheimer’s disease (AD). In November 2025, a rolling sBLA application to the U.S. FDA for the subcutaneous initiation dosing with Leqembi Iqlik was also completed and a new drug application for subcutaneous formulation of Leqembi was submitted in Japan. In December 2025, Lecanemab has been included in the “Commercial Insurance Innovative Drug List”, recently introduced by the National Healthcare Security Administration (NHSA) of China. 

    Since July 2020, Eisai’s Phase 3 clinical study (AHEAD 3-45) with lecanemab in individuals with preclinical Alzheimer’s disease meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. The study was fully recruited in October 2024. AHEAD 3-45 is a four-year study conducted as a public-private partnership between Eisai, Biogen and the Alzheimer’s Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S., funded by the National Institute on Aging, part of the National Institutes of Health. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.

    About the collaboration between BioArctic and Eisai
    Since 2005, BioArctic has a long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of Alzheimer’s disease. The most important agreements are the Development and Commercialization agreement for the lecanemab antibody, which was signed 2007, and the Development and Commercialization agreement for the antibody Leqembi back-up for Alzheimer’s disease, which was signed 2015. In 2014, Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer’s disease. BioArctic has the right to commercialize lecanemab in the Nordic region and is currently preparing for commercialization in the Nordics together with Eisai. BioArctic has no development costs for lecanemab in Alzheimer’s disease and is entitled to payments in connection with sales milestones as well as royalties on global sales.

    About BioArctic AB
    BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world’s first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer’s disease. Leqembi has been developed together with BioArctic’s partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson’s disease and ALS as well as additional projects against Alzheimer’s disease. Several of the projects utilize the company’s proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic’s B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.

    [1] Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi:10.1038/s41467-021-23507-z.

    [2] Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer’s Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.

    [3] Hampel H, Hardy J, Blennow K, et al. The amyloid-β pathway in Alzheimer’s disease. Mol Psychiatry. 2021;26(10):5481-5503.

    This information was brought to you by Cision http://news.cision.com

    https://news.cision.com/bioarctic/r/leqembi–iqlik—lecanemab-irmb–supplemental-biologics-license-application-regarding-subcutaneous-s,c4297439

    The following files are available for download:

    Continue Reading

  • A global markets correction may be coming, warn veterans

    A global markets correction may be coming, warn veterans

    Continue Reading

  • Needham Reiterates Buy on Docebo Inc. (DCBO), Sees Significant Upside From Current Levels

    Needham Reiterates Buy on Docebo Inc. (DCBO), Sees Significant Upside From Current Levels

    We recently published an article titled 9 High Growth Canadian Stocks to Buy. 

    Another high-growth Canadian stock to buy, Docebo Inc. (NASDAQ:DCBO) is an education technology company established in 2005. The company is known for Docebo Learn, its core learning management system offering. Docebo lists its shares on both the Toronto Stock Exchange and the Nasdaq Global Select Market.

    On January 20, Needham analyst reiterated a Buy rating on Docebo Inc. (NASDAQ:DCBO) and set a price target of $38.00. Overall analyst sentiment on the stock remains highly positive, with a Strong Buy consensus and an average price target of $35.33, implying upside potential of roughly 84%. Craig-Hallum has also reaffirmed its Buy rating on the shares.

    During its Q3 2025 earnings call, Docebo Inc. (NASDAQ:DCBO) highlighted plans to continue growing its base of customers generating more than $100,000 in annual contract value, underscoring solid momentum across the enterprise and mid-market segments. Management pointed to notable new customer wins such as Veolia, alongside expanded adoption within existing clients, including Amazon, as evidence of sustained demand and deeper platform penetration.

    Docebo Inc. (NASDAQ:DCBO) also announced the introduction of a credit-based pricing model for its AI-powered modules, including AI Virtual Coach and AI Video Presenter. This approach not only enhances flexibility for customers but also creates a clear pathway for incremental monetization over time, while reinforcing Docebo’s broader strategy of embedding artificial intelligence more deeply across its product suite.

    While we acknowledge the potential of DCBO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

    READ NEXT: 13 Best Dividend Kings to Buy in 2026 and 14 Best Mid Cap Dividend Aristocrat Stocks to Buy Now

    Disclosure: None.

    Continue Reading

  • U.S. stock futures fall, gold hits record ahead of Fed meeting, Big Tech earnings

    U.S. stock futures fall, gold hits record ahead of Fed meeting, Big Tech earnings

    By Mike Murphy

    A worker shovels snow outside the New York Stock Exchange on Sunday.

    U.S. stock futures slumped and gold hit a record high Sunday as investors look ahead to a Fed interest-rate decision and Big Tech earnings this week.

    Dow Jones Industrial Average futures (YM00) fell more than 200 points, or 0.4%, late Sunday. S&P 500 futures (ES00) dropped 0.6 and Nasdaq-100 futures (NQ00) fell 0.8%, after Intel’s 17% plunge Friday.

    Gold futures (GC00) topped $5,000 an ounce for the first time, rising as high as $5,029 on Sunday. Gold is up 15% year to date, and has surged 79% over the past year. Silver futures (SI00), which last week hit $100 an ounce for the first time, continued to surge Sunday. Silver has rallied more than 45% in 2026, and is up more than 230% over the past year.

    Bitcoin (BTCUSD) slumped over the weekend, and was last trading around $86,400. West Texas crude (CL.1), the U.S. benchmark, dipped, and the ICE U.S. Dollar Index DXY, which compares the buck against a basket of rival currencies, declined 0.5% after the dollar lost 1.7% against the Japanese yen USDJPY on Friday

    Stocks mostly gained Friday, but ended the week lower. The S&P 500 SPX dipped 0.4% on the week, while the Dow DJIA declined 0.5% and the Nasdaq COMP slipped 0.1%. All three benchmarks suffered their second straight weekly declines, according to Dow Jones Market Data.

    The Federal Reserve’s interest-rate-setting committee meets Tuesday and Wednesday, with Fed Chair Jerome Powell expected to speak after its conclusion. Most economists and investors are expecting the Fed to keep rates unchanged, with perhaps no more rate cuts until summer – or even later. While inflation remains sticky and the job market is stagnant, Fed officials reportedly worry that more rate cuts could drive up inflation.

    Read more: The Fed is expected to stand pat this week. The big question is for how long?

    Wednesday will also bring quarterly earnings reports for three of the “Magnificent Seven” tech giants: Microsoft (MSFT), Facebook parent Meta (META) and Tesla (TSLA). Apple (AAPL) will report earnings Thursday.

    Big Tech weighs heavily on the S&P 500, and has helped drive strong gains for the overall market in recent years. But as AI infrastructure spending continues to rise sharply without showing big results – yet – investors are getting wary, and broadening their investments to non-tech sectors. That could be good news for the wider market, giving it more durability and making it less reliant on a handful of stocks.

    The upcoming “Magnificent Seven” companies’ earnings will show how those industry leaders are faring amid that cyclical trading, with eyes particularly on Apple and Google parent Alphabet, which reports Feb. 4.

    More: These 5 tech stocks could be big winners this earnings season

    Last week, markets were roiled by tariff threats – and their subsequent retraction – from President Donald Trump against eight of America’s European allies who oppose his desire to acquire Greenland.

    On Saturday, Trump again raised the specter of tariffs against a close ally, threatening Canada with new 100% levies if it goes ahead with a trade deal with China. “We can’t let Canada become an opening that the Chinese pour their cheap goods into the U.S,” U.S. Treasury Secretary Scott Bessent said Sunday during an interview on ABC’s “This Week.”

    But Canadian Prime Minister Mark Carney said Sunday his country has no plans for a free-trade agreement with China, and said a recent deal with China merely resolved some tariff-quota issues between the two countries.

    Furthermore, a little over a week ago, Trump said it was “OK” for Carney to sign a trade deal with China. “That’s what he should be doing. I mean, it’s a good thing for him to sign a trade deal. If you can get a deal with China, he should do that,” Trump told White House reporters on Jan. 15.

    -Mike Murphy

    This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

    (END) Dow Jones Newswires

    01-25-26 1837ET

    Copyright (c) 2026 Dow Jones & Company, Inc.

    Continue Reading

  • Assessing Centerra Gold (TSX:CG) Valuation After High Conviction Upgrade And Key Project Milestones

    Assessing Centerra Gold (TSX:CG) Valuation After High Conviction Upgrade And Key Project Milestones

    Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.

    Centerra Gold (TSX:CG) is back in focus after a leading brokerage moved the stock to its highest conviction rating, pointing to fresh permitting at Mount Milligan and updated economics at the Kemess copper gold project.

    See our latest analysis for Centerra Gold.

    Those permitting wins and the Kemess update have arrived alongside sharp market interest, with a 30 day share price return of 23.72% and a 90 day share price return of 66.27%, while the 1 year total shareholder return of 195.44% points to strong momentum that investors are now reassessing in light of Centerra Gold’s expanded project pipeline.

    If you are tracking how miners are repricing on new project news, it can help to widen the lens and see what else is moving among fast growing stocks with high insider ownership.

    With Centerra Gold shares up strongly over the past year and the stock now trading just under its CA$28.15 analyst price target and near its estimated intrinsic value, the key question is whether there is still a buying opportunity here or if the market is already pricing in future growth.

    Compared with the current CA$25.19 share price, the most followed narrative pegs Centerra Gold’s fair value at about CA$21.47, implying a premium that investors may want to unpack before leaning on recent momentum.

    The analyst price target for Centerra Gold has ticked higher by about C$0.25, with analysts pointing to updated fair value estimates, modest tweaks to discount and growth assumptions, as well as a lower projected future P/E multiple as key supports for the change.

    Read the complete narrative.

    Curious what supports that higher target even as the future earnings multiple comes down and margin assumptions shift? The most followed narrative blends projected revenue growth, profitability changes and a specific discount rate into one fair value line. If you want to see exactly which earnings and cash flow paths are doing the heavy lifting in that model, the full narrative walks through every step of the calculation.

    Result: Fair Value of CA$21.47 (OVERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, that fair value story can shift quickly if Mount Milligan’s grade uncertainty persists, or if higher all in sustaining costs squeeze margins at current gold prices.

    Find out about the key risks to this Centerra Gold narrative.

    While the most followed narrative sees Centerra Gold as 17% overvalued versus its CA$21.47 fair value line, the current P/E of 11x tells a different story. That multiple sits well below the Canadian Metals and Mining industry at 27.8x and peers at 35.2x, and also below a 14.9x fair ratio that the market could eventually lean toward. This raises the question of whether recent share price strength has fully closed that gap or not.

    See what the numbers say about this price — find out in our valuation breakdown.

    TSX:CG P/E Ratio as at Jan 2026

    If you look at this view and feel it misses something, or you simply prefer your own work, you can build a custom story in minutes with Do it your way.

    A great starting point for your Centerra Gold research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.

    If you are serious about sharpening your watchlist, do not stop at one story. Use the Simply Wall St Screener to surface fresh, data driven stock ideas fast.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include CG.TO.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • A Look At M/I Homes (MHO) Valuation As Shares Trade Below Popular Fair Value Estimates

    A Look At M/I Homes (MHO) Valuation As Shares Trade Below Popular Fair Value Estimates

    Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.

    M/I Homes (MHO) is back on investors’ radar after recent share price moves, with the stock closing at $133.45. You might be weighing how this homebuilder’s latest performance fits into your portfolio today.

    See our latest analysis for M/I Homes.

    That latest move to $133.45 comes after a mixed short term stretch, with a 1 day share price return of 1.69% decline and a 7 day share price return of 2.70% decline, set against a 3 year total shareholder return of 126.53% and 5 year total shareholder return of 170.31%. This combination points to strong longer term momentum despite recent softness.

    If M/I Homes has you rethinking where housing fits in your portfolio, this could be a useful moment to compare it with other fast growing stocks with high insider ownership that are catching attention right now.

    With annual revenue and net income both showing recent declines, yet the share price sitting below the average analyst target of $157, you have to ask yourself: is M/I Homes undervalued, or is the market already pricing in future growth?

    With M/I Homes closing at $133.45 against a most-followed fair value estimate of $157, the current price sits well below that narrative benchmark.

    Strong balance sheet fundamentals (record-high equity, substantial cash reserves, low net debt, and aggressive share repurchases) not only provide downside protection but also amplify future earnings per share (EPS) and return on equity as demand and deliveries ramp up.

    Read the complete narrative.

    Analysts are tying this fair value to a detailed mix of revenue expectations, margin assumptions, and future P/E levels. Curious which input carries the most weight here, and how buybacks factor into the earnings path behind that $157 figure.

    Result: Fair Value of $157 (UNDERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, you still need to factor in the risk that softer new contracts and rising inventory exposure could pressure margins and weaken the case for upside.

    Find out about the key risks to this M/I Homes narrative.

    While the fair value narrative of $157 suggests upside, the Simply Wall St DCF model lands in a very different place, with an estimate of $38.03 per share. This would make the current $133.45 price look expensive rather than cheap. As an investor, which story do you trust more, the earnings path or the cash flows?

    Look into how the SWS DCF model arrives at its fair value.

    MHO Discounted Cash Flow as at Jan 2026

    Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out M/I Homes for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 871 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match – so you never miss a potential opportunity.

    If you are not fully aligned with these narratives or prefer to lean on your own work, you can test the numbers yourself in just a few minutes, then Do it your way.

    A great starting point for your M/I Homes research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

    If M/I Homes has sharpened your focus, do not stop here. The next step is to line up a few fresh watchlist candidates using focused screeners.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include MHO.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Merck no longer in talks to buy Revolution Medicines, WSJ reports – Reuters

    1. Merck no longer in talks to buy Revolution Medicines, WSJ reports  Reuters
    2. Exclusive | Merck No Longer in Talks to Buy Revolution Medicines  The Wall Street Journal
    3. Merck (MRK) Ends Acquisition Talks with Revolution Medicines Valued at $30 Billion  Intellectia AI
    4. Merck no longer in talks to acquire Revolution Medicines, WSJ reports  TipRanks
    5. Merck Ends Talks to Acquire Revolution Medicines, WSJ Reports  Bloomberg

    Continue Reading

  • Amsterdam prepares to ‘ban the fatbikes’ amid rise in serious accidents | Netherlands

    Amsterdam prepares to ‘ban the fatbikes’ amid rise in serious accidents | Netherlands

    On a busy lunchtime, thick-tyred electric bikes zoom through the leafy lanes of the Vondelpark in Amsterdam. But after a marked rise in accidents – particularly involving children – these vehicles the Dutch call “fatbikes” are to be banned in some parts of the Netherlands.

    “It’s nonsense!” said Henk Hendrik Wolthers, 69, from the saddle of his wide-tyred, electric Mate bike. “I drive a car, I ride a motorbike, I’ve had a moped and now I ride a fatbike. This is the quickest means of transport in the city and you should be able to use it.”

    An increasing number of road safety experts, doctors and politicians in the Netherlands disagree. Although motor assistance on e-bikes is limited to just over 15mph, many fatbike riders modify the factory settings to reach speeds of 25mph in this busy park.

    The safety organisation VeiligheidNL estimates that 5,000 fatbike riders are treated in A&E departments each year, on the basis of a recent sample of hospitals. “And we also see that especially these young people aged from 12 to 15 have the most accidents,” said the spokesperson Tom de Beus.

    The Vondelpark will become a fatbike-free area of the city once the new measures are brought in. Photograph: Piroschka Van De Wouw/Reuters

    Now Amsterdam’s head of transport, Melanie van der Horst, has said “unorthodox measures” are needed and has announced that she will ban these heavy electric bikes from city parks, starting in the Vondelpark. Like the city of Enschede, which is also drawing up a city centre ban, she is acting on a stream of requests “begging me to ban the fatbikes”.

    In the park, her plans stirred mixed reactions. While four in five fatbike riders who whizzed past said they were “too busy” to talk, 31-year-old Joost was sceptical. “It will be senseless,” he said. “Normal bicycles use the park, city vehicles use it. It’s all about having the appropriate speed.”

    But Muriel Winkel, 33, running with her dog, Joop, was enthusiastic. “They are all souped-up, which people don’t do with evil intentions, but they often ride carelessly, without watching out,” she said. “Sometimes, my dog really gets a fright.”

    Some point out that the tensions around electric bikes will soon reach other countries, especially with more political interest in stimulating active mobility.

    In this land of early adopters, 48% of bicycles sold in 2024 were electric and another 13% were fatbikes, according to figures from RAI Vereniging and BOVAG motoring associations. In Amsterdam, a third of journeys are made by cycling.

    The roadside assistance organisation ANWB said that the problem was not necessarily with the wide-tyred bike model – but the ease with which people could speed it up to use like a moped, “combined with risky behaviour”.

    Florrie de Pater, the chair of the Fietsersbond Amsterdam cycling association, said that the rise of illegal bikes, plus a lack of enforcement, was scaring old people and children off the roads. “Because of the dangers of those who are cycling fast, especially older people over 55 or 60 simply leave their bikes at home,” she said. “We also hear that parents no longer dare to let their children cycle to school.”

    The brain injury specialist Marcel Aries, a consultant at Maastricht University Medical Center, said more authorities needed to consider controversial bans, alongside the helmet requirement for children on electric bikes from 2027. “It is reasonable for governments and municipalities to consider measures that may be unpopular,” he said. “They are public health responses to increasingly congested streets and widening speed gaps between cars, cyclists and pedestrians.”

    His view is shared by Marlies Schijven, a professor of surgery at the Amsterdam University Medical Center, whose frustrated LinkedIn post on dangerous riders in 2024 has been viewed 2.9m times. “It is a good step, but a baby step, only in one Amsterdam park,” she said. “The problem is much larger. We still see pain, misery and death every day at our morning meeting in the hospital.”

    Wolthers, the fatbike owner, agreed that the problem was in letting children ride these powerful vehicles. “Children go through red, they don’t signal and they also can’t assess the traffic,” he said. “Hospitals have a chilling term for them: potential donors.”

    Continue Reading

  • Pregnancy-Triggered Vaso-Occlusive Crises in Hemoglobin SE Disease Complicated by Glucose-6-Phosphate Dehydrogenase Deficiency: A Case Report

    Pregnancy-Triggered Vaso-Occlusive Crises in Hemoglobin SE Disease Complicated by Glucose-6-Phosphate Dehydrogenase Deficiency: A Case Report

    Continue Reading

  • The looming risk of food shortages and anarchy in the UK | Farming

    The looming risk of food shortages and anarchy in the UK | Farming

    Your case for the accumulation of public food reserves in the UK, to ensure that we can feed the nation in the event of war, trade disagreements or world shortages, is well made (Editorial, 20 January). We are rapidly moving into times where the risks of such scenarios are high. Without food for its population, the UK would face economic and political breakdown and anarchy.

    You mention the urgent need to accumulate national stocks of food supplies, probably mostly imported, but say nothing about the UK’s own capacity to produce its own food supply from the agricultural and horticultural industries. In a lengthy period of worldwide food shortage, this would be the only way of avoiding food shortages.

    Following the food shortages of the second world war, we did reach a level of 78% self-sufficiency in 1984, but this has gradually fallen to 62%. This level of home production is about to decline rapidly as the demand for land from a range of other more lucrative uses continues to grow. House- and road-building, the use of agricultural land for woodland and other carbon-saving purposes, solar farms, the creation of new wildlife habitats, recreational use and the general unprofitability of farming will see our self-sufficiency fall again over the next decade. The government’s own land use framework predicts a 10% reduction in farmland by 2050, but this is likely far short of reality.

    These alternative uses of land are all beneficial and desirable, but are they ultimately more important than feeding the population? Most other countries do not think so.
    Richard Harvey
    Owston, Leicestershire

    Have an opinion on anything you’ve read in the Guardian today? Please email us your letter and it will be considered for publication in our letters section.

    Continue Reading